Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
Credit: Dana-Farber Cancer Institute After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared...









